Villaret Andrea Bolzoni, Piazza Cesare, Peretti Giorgio, Calabrese Luca, Ansarin Mohssen, Chiesa Fausto, Pellini Raul, Spriano Giuseppe, Nicolai Piero
Department of Otorhinolaryngology, University of Brescia, Piazza Spedali Civili 1, 25123 Brescia, Italy.
Arch Otolaryngol Head Neck Surg. 2007 Sep;133(9):897-903. doi: 10.1001/archotol.133.9.897.
To evaluate the prevalence of sublevel IIB lymph node (LN) metastases for head and neck primary tumors in a large cohort of patients.
Prospective study.
One referral university hospital and 2 national institutes of oncology.
Between 2003 and 2005, 297 patients (male to female ratio, 3.5:1; mean age, 58.8 years [range, 18-89 years]) affected by head and neck cancer were treated by surgery on the primary tumor and/or the neck. Primary site distribution included the following: oral cavity in 111 patients, larynx in 92, oropharynx in 32, thyroid gland in 22, skin of the lateral face or scalp in 16, hypopharynx in 11, unknown primary in 7, and parotid gland in 6. Sublevel IIB was evaluated for the number of LNs and pathologic N (pN) status.
All patients underwent unilateral or bilateral neck dissection (ND) with therapeutic or elective intent according to the primary site and clinical T (cT) and clinical N (cN) status. Sublevel IIB was selectively dissected at the beginning of ND, labeled, and processed independently.
The distribution of metastases among the different levels was analyzed. The influence of several factors (institution in which the surgical procedure was performed, sex of the patient, site of primary, histotype, pathologic T [pT] status, cN status, lower level involved in the neck together with sublevel IIB, association with sublevel IIA metastasis, ipsilateral number of involved levels, and previous surgical treatment limited on the primary site) on the prevalence of sublevel IIB metastasis was statistically evaluated by the Pearson chi(2) test or Fisher exact test.
A total of 443 NDs were performed (unilateral in 151 patients and bilateral in 146). Among the patients, the tumors were staged cN0/pN0 in 27%, cN+/pN+ in 50%, cN+/pN0 in 7%, and cN0/pN+ in 16%. The mean number of LNs collected at sublevel IIB was 5.4 (range, 0-24). The overall prevalence of sublevel IIB metastases was 5.6% (26 neck sides). Tumor histologic type in the sublevel IIB+ population was squamous cell carcinoma in 80%, papillary carcinoma in 8%, melanoma in 8%, and adenocarcinoma in 4%. The chi(2) test showed a significantly higher risk for LN metastases at sublevel IIB in patients affected by parotid gland primary tumors (33%), tumors of the skin or scalp (25%), unknown primary tumors (14%), and cancers of the oral cavity (10%) (P = .02) and in those clinically staged as cN+ (P < .001).
Sublevel IIB dissection is strongly recommended for all patients with cN+ tumors and in those affected by tumor of the parotid gland, skin, and scalp scheduled for elective ND. Patients affected by laryngeal cancer scheduled for elective ND can be considered the ideal candidates for preservation of sublevel IIB. However, whether this policy could be associated with a better functional outcome remains to be demonstrated by prospective studies on a large series of patients.
评估一大群患者中头颈部原发性肿瘤IIB亚组淋巴结(LN)转移的发生率。
前瞻性研究。
一家转诊大学医院和两家国家肿瘤研究所。
2003年至2005年间,297例头颈部癌患者(男女比例为3.5:1;平均年龄58.8岁[范围18 - 89岁])接受了原发肿瘤和/或颈部手术治疗。原发部位分布如下:口腔111例,喉92例,口咽32例,甲状腺22例,侧面或头皮皮肤16例,下咽11例,原发灶不明7例,腮腺6例。对IIB亚组的淋巴结数量和病理N(pN)状态进行评估。
所有患者根据原发部位以及临床T(cT)和临床N(cN)状态,进行了具有治疗或择期目的的单侧或双侧颈清扫术(ND)。在ND开始时选择性清扫IIB亚组,标记并独立处理。
分析不同层面转移的分布情况。通过Pearson卡方检验或Fisher确切检验,对几个因素(进行手术的机构、患者性别、原发部位、组织学类型、病理T[pT]状态、cN状态、与IIB亚组一起受累的颈部更低层面、与IIA亚组转移的关联、同侧受累层面数量以及原发部位的既往手术治疗受限情况)对IIB亚组转移发生率的影响进行统计学评估。
共进行了443例颈清扫术(151例单侧,146例双侧)。患者中,肿瘤分期为cN0/pN0的占27%,cN+/pN+的占50%,cN+/pN0的占7%,cN0/pN+的占16%。IIB亚组收集的淋巴结平均数量为5.4个(范围0 - 24个)。IIB亚组转移的总体发生率为5.6%(26侧颈部)。IIB +人群中的肿瘤组织学类型为鳞状细胞癌占80%,乳头状癌占8%,黑色素瘤占8%,腺癌占4%。卡方检验显示,腮腺原发性肿瘤患者(33%)、皮肤或头皮肿瘤患者(25%)、原发灶不明肿瘤患者(14%)和口腔癌患者(10%)(P = 0.02)以及临床分期为cN +的患者(P < 0.001)在IIB亚组发生LN转移的风险显著更高。
强烈建议对所有cN +肿瘤患者以及计划进行择期ND的腮腺、皮肤和头皮肿瘤患者进行IIB亚组清扫。计划进行择期ND的喉癌患者可被视为保留IIB亚组的理想人选。然而,这一策略是否能带来更好的功能结果仍有待对大量患者进行前瞻性研究来证实。